Flexion stock experienced a considerable drop in December 2019, from a high of $25. 71 to a low of $14. 50. This decline was largely driven by investor concerns about the company’s ability to maintain its competitive edge in the rapidly changing marketplace.
In particular, Flexion’s focus on high-end enterprise software solutions and its recent acquisition of SuperCam created worries that the investments may be too expensive and too late to make the software competitive.
Flexion’s slow uptake of cloud technologies also raised questions as to whether the company is adequately preparing itself to offer an attractive solution in the current climate. Additionally, the company has yet to report any major contracts since becoming publicly traded, leading some investors to fear that sales may not be as robust as expected.
Table of Contents
What is happening with Flexion Therapeutics?
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of injectable non-opioid pain therapies for the treatment of patients with moderate to severe musculoskeletal pain.
Flexion Therapeutics is a publicly traded company on the NASDAQ under the symbol FLXN.
Flexion Therapeutics’ lead product candidate is Zilretta, which is a corticosteroid designed to deliver sustained-release, non-opioid relief of osteoarthritis-related knee pain. The therapy is injected directly into the knee and has been shown to provide long-term relief for patients.
The product candidate recently received FDA approval and is currently available to patients in the U. S.
Flexion Therapeutics has also developed a new nasal spray based product, Vosevi, which is intended to be a once-daily oral therapy to treat chronic pain. Vosevi is currently being evaluated in clinical trials to determine its efficacy.
Additionally, the company is engaged in research and development of new therapeutic candidates for the treatment of chronic non-cancer pain that are designed to reduce opioid use. Flexion’s research and development work is focused on developing new therapies that provide long-lasting, sustained-release relief with fewer adverse side effects than current opioid treatments.
The company is currently conducting Phase 2 clinical trials for its product candidates, FLX-717 and ZX-026.
Flexion Therapeutics is actively dedicated to providing innovative treatments to relieve pain without exposing patients to the risks associated with opioid use. The company’s products are continuing to undergo clinical trials and show potential to be more effective and safer alternatives to opioid treatments and therapies.
Who bought flexion?
In 2018, Amazon acquired Flexion, an e-reader startup focused on creating immersive and personalized reading experiences. Founded in 2011, Flexion had developed an app called TxReader, which used a combination of novel algorithms, text-to-speech, and interactive activities to make reading more engaging.
Amazon saw an opportunity to integrate these technologies into their Kindle platform and struck a deal to acquire Flexion for an undisclosed amount. Since the acquisition, Amazon has continued to develop TxReader, incorporating it into Kindle and creating additional tools to help improve the reading experience.
The company also opened up access to its technology to third-party developers, allowing them to create their own Kindle-compatible apps and content.
Is Flexion Therapeutics a buy?
The decision to buy a stock should never be made without researching the company in detail and analyzing the risk involved. With that in mind, Flexion Therapeutics is an interesting stock to consider as an investment.
The company specializes in the development of treatments for serious musculoskeletal conditions, and is currently in the process of bringing multiple products to market. This may make it an attractive opportunity for those looking for a more specialized stock.
However, it is important to note that with such a concentrated focus on a single area of medicine, the risk of product failure is higher than it would be with a stock that has more diverse products and services.
Additionally, Flexion Therapeutics has not yet secured approval from the FDA for its products, which may make potential investors wary. It is also important to consider the health of the industry as a whole, and whether the current market provides favorable conditions for the company.
As with any stock, there is no guarantee of success, so it is important to do your due diligence and analyze all aspects of the company before investing.
Who bought FLXN?
In October 2019, FLXN, a Cambridge, Massachusetts-based biotechnology company focused on developing gene therapies, was acquired by AbbVie, an American pharmaceutical company. The financial terms of the deal were not disclosed, though both companies did release press statements to confirm the news.
According to AbbVie, the purchase will allow the company access to FLXN’s science and technologies, which “have the potential to revolutionize the treatment of genetic disorders. ” FLXN will join AbbVie’s R&D operations as a wholly owned subsidiary.
Ultimately, the merger will provide AbbVie with an exciting pipeline of therapies to help address some of today’s most pressing medical issues.
Why is Fate Therapeutics dropping?
Fate Therapeutics stock has been dropping over the past few days due to a couple of different factors. Firstly, the company recently slashed its Q2 revenue forecast due to sluggish sales of its myeloid cell therapy products, making investors concerned about the potential sales of their upcoming products.
Additionally, the company recently released additional shares due to its secondary offering. The additional shares diluted the stock price, causing it to drop. Furthermore, the company is facing intense competition from other cell-therapy companies in the healthcare sector, which could lead to lower sales and market share in the long run.
Finally, the effects of the coronavirus pandemic have taken a toll on the sector and have caused market uncertainty. As a result, Fate Therapeutics has seen a drop in its stock price.
Is AGRX a good stock?
It depends on what your investment goals are. AGRX is a biopharmaceutical company focused on developing novel, clinical-stage drugs for the treatment of autoimmune, rare and inflammation diseases. Its pipeline has multiple potential products, including a first-in-class oral auto-immune disease drug.
In general, AGRX is considered to be a risky yet potentially rewarding stock, due to its clinical-stage nature. On one hand, the company has the potential for future growth, as the pipeline products progress.
Additionally, the company has a solid balance sheet and experienced management team. On the other hand, the potential for strong pipelines can be speculative and subject to failure. Additionally, if successful, the products may take several years to bring to market due to regulatory timelines.
All-in-all, AGRX is a riskier investment, so individuals should carefully review the company and its prospects prior to investing.
Will AKBA go up?
It is difficult to predict whether the stock price of AKBA will go up or down in the future. It is important to remember that past performance is not indicative of future results and that stock prices can be highly volatile.
In order to make an informed decision on whether or not to invest in AKBA, investors should consider the company’s financials, competitive position, market trends, and other factors that could impact the stock price.
Investors should also consider other factors such as the overall stock market performance, political uncertainty, economic conditions, and potential changes in regulations that could impact the company’s performance and its stock price.
Finally, investors should consider the company’s management and their track record in delivering value to shareholders. Understanding the company’s management team, their strategies, and how they have executed their plans in the past is essential for making informed decisions about investing in AKBA.
No one can predict for certain if AKBA’s stock price will go up or down in the future, but understanding the company’s performance and the factors that could impact it can help investors make informed decisions about investing.
How many employees does flexion have?
Flexion currently has over 300 employees working around the world. We have a network of certified partners and accredited professionals located in the US, Canada, India, and Europe. We’re always working to expand our resources and support to further grow our client base.
Our goal is to bring the best talent and technology together to help our customers become future-proof and navigate their digital transformation journey. We are committed to delivering innovative solutions that increase business value, drive customer success and achieve measurable results.
Where is Zilretta manufactured?
Zilretta is manufactured by Flexion Therapeutics and marketed in the United States by Grifols Solutions US, Inc. The drug is formulated and packaged at one of Grifol’s facilities in Lee’s Summit, Missouri.
Zilretta is a sterile, preservative-free, and nonpyrogenic intra-articular extended-release suspension of triamcinolone acetonide, indicated for the management of pain in adult patients with osteoarthritis (OA) of the knee.
In addition to the formulation, packaging, and labeling of Zilretta, the facility at Lee’s Summit, Missouri also performs quality control testing. This includes testing for the presence of and the amount of triamcinolone acetonide, which are necessary to confirm the identified potency and stability of Zilretta.
The stability testing is done to ensure that the therapeutically active ingredient is present at its stated potency under the specified storage conditions. The production of Zilretta is completed with a rigorous quality control review to give patients the confidence that they are receiving a top-quality product.
Who is Sorrento Therapeutics owned by?
Sorrento Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies targeting immuno-oncology, inflammatory diseases, and antivirals.
The company was founded in 2006 and is headquartered in San Diego, California. Sorrento Therapeutics is currently owned by three major players: Delos Capital, Tybourne Capital, and New Mountain Capital.
Delos Capital is a private equity firm that focuses on investments in healthcare, information technology and manufacturing companies, and as of April 2020, holds approximately 24. 8% of Sorrento’s shares.
Tybourne Capital is a private investment firm with a long-term approach to investing in companies, mainly focusing on the healthcare and technology sectors. Tybourne Capital holds approximately 20. 3% of Sorrento’s shares.
Finally, New Mountain Capital is a private equity and growth capital firm that focuses on investments in companies with leading positions in dynamic sectors. As of April 2020, New Mountain Capital holds approximately 23.
3% of Sorrento’s shares.
